-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune checkpoint inhibitors show high response rates and long-lasting clinical benefits in tumors with microsatellite instability-high/mismatch repair defects (MSI-H/dMMR)
immunity
This is a phase 1b clinical trial to evaluate the safety and anti-tumor activity of anti-PD-L1 antibody LY3300054 as a single agent or in combination with anti-TIM-3 antibody LY3321367 in patients with advanced solid tumors of MSI-H/dMMR
Enrolled 18-year-old patients with solid tumors who have not previously received anti-PD-1/PD-L1 therapy, and were treated with LY3300054 as a single agent (n=40) or combined with LY3321367 (n=20); for PD-1/PD -L1 inhibitor-resistant/refractory tumor patients received combination therapy (n=22)
A total of 82 patients were recruited, the most being colorectal tumors (n=39, 47.
The occurrence of TRAE in the two groups
The occurrence of TRAE in the two groupsThe incidence of treatment-related adverse events (TRAE) in the single-drug cohort, PD-1/PD-L1 inhibitor-initial combined cohort, and PD-1/PD-L1 inhibitor-resistant/refractory combined cohort were respectively 55.
The incidence of treatment-related adverse events (TRAE) in the single-drug cohort, PD-1/PD-L1 inhibitor-initial combined cohort, and PD-1/PD-L1 inhibitor-resistant/refractory combined cohort were respectively 55.
Various efficacy evaluation results of the two groups
Various efficacy evaluation results of the two groupsThe objective response rates of the single-drug cohort, PD-1/PD-L1 inhibitor-initial combined cohort, and PD-1/PD-L1 inhibitor resistant/refractory combined cohort were 32.
The objective response rates of the single-drug cohort, PD-1/PD-L1 inhibitor-initial combined cohort, and PD-1/PD-L1 inhibitor resistant/refractory combined cohort were 32.
Both LY3300054 monotherapy and LY3300054/anti-TIM-3 combination therapy have controllable safety
Original source:
Antoine Hollebecque, et al.
Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors.
Leave a message here
